Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sonoma Pharmaceuticals Inc (NQ: SNOA )

0.1600 +0.0010 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sonoma Pharmaceuticals Inc

< Previous 1 2 Next >
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
Via ACCESSWIRE
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
Via ACCESSWIRE
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
Via ACCESSWIRE
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results
Via ACCESSWIRE
These Four Companies Are Attracting Investors Following Recent News
Via AB Newswire
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference
Via ACCESSWIRE
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock
Via ACCESSWIRE
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board
Via ACCESSWIRE
Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union
Via ACCESSWIRE
Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care
Via ACCESSWIRE
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia
Via ACCESSWIRE
Sonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade Disinfectant
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea
Via ACCESSWIRE
Sonoma Pharmaceuticals (NASDAQ: SNOA) and EMC Pharma Receives DAPA Registration for Microcyn Rx Products from U.S. Department of Defense
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) is a global healthcare company that is focused on the research, development and production of 
Via Spotlight Growth
Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products
Via ACCESSWIRE
Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical Supply
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results
WOODSTOCK, GA / ACCESSWIRE / July 13, 2022 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous... 
From Sonoma Pharmaceuticals, Inc.
Via AccessWire
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.
From Sonoma Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.